

Smith & Nephew

All parts now in place to move forward

Smith & Nephew (S&N) delivered a fair Q4 and FY16, which were affected by tough market conditions in China and the Gulf states. However, the company has announced that its fundamental restructuring is complete, enabling a stronger 2017 and beyond.

FY16 affected by tough market conditions

S&N reported trading profits of \$1.02bn, down 7% on 2015, on revenues of \$4.67bn vs \$4.63bn respectively. This was a 190bp reduction in trading profit margin principally due to a foreign exchange headwind (120bp), the Bluebelt acquisition (60bp), and divestment of the gynaecology business. Also, underlying revenue growth of 2% was in line with consensus (reported revenue +1%) but affected by tough market conditions in China and the Gulf states. These impacts were partially offset by the group optimisation programme. It is important to note that, apart from the weakness in China and the Gulf states, the rest of the emerging markets demonstrated double-digit growth. Performance across the year was primarily driven by S&N's sports medicine joint repair division (8% growth) and its other surgical businesses division, which includes ENT and NAVIO robotic sales (15% growth). Advanced wound care and trauma & extremities were the worst performers, affected by weakness in China, UK and Germany, with revenue down 3% and 4% respectively.

Outlook for 2017

S&N expects stronger revenue growth in 2017 (3-4% underlying) and an improvement in trading profit margin (20-70bp). It states it will be able to deliver this through improved execution now the fundamental restructuring is complete and through continued focus on efficiency. We believe that, alongside its increased focus on innovation, this will deliver improved growth and margin. It has a strong near-term pipeline of product lines (eg REDAPT revision hip, COBLATION WEREWOLF, JOURNEY II Knee), which it can build on. Innovations that offer a strong value proposition such as improved cost effectiveness and outcomes will enable expansion in high-growth market segments.

Valuation: Improving prospects underpins premium

S&N currently trades at 17.1x 2017e P/E, in line with the average of US peers Stryker and Zimmer at c 19x and 14x, respectively. We believe the premium to the average valuation is underpinned by evidence of improving growth prospects, which could see S&N closing the 10% premium that Stryker trades at (due, in our opinion, to its improved portfolio balance and its leading the robotics focus).

Consensus estimates

| Year end | Revenue (\$m) | PBT (\$m) | EPSA* (c) | DPS (c) | P/E (x) | Yield (%) |
|----------|---------------|-----------|-----------|---------|---------|-----------|
| 12/15 | 4634 | 1040 | 85.1 | 30.8 | 17.5 | 2.1 |
| 12/16 | 4669 | 965 | 82.6 | 30.8 | 18.0 | 2.1 |
| 12/17e | 4782 | 1009 | 87.0 | 32.4 | 17.1 | 2.2 |
| 12/18e | 4977 | 1079 | 94.6 | 35.5 | 15.7 | 2.4 |

Source: Smith & Nephew, Bloomberg. Note: *Before amortisation of intangibles.

Healthcare equipment & services

14 February 2017

Price 1,189p

Market cap £11bn

£1:\$1.25

Share price graph



Share details

| | |
|-----------------|------|
| Code | SN |
| Listing | LSE |
| Shares in issue | 886m |

Business description

Smith & Nephew is a leading UK-based maker of medical devices. It is the world's number one in arthroscopy products; two in advanced wound management; three in trauma and extremities products; and number four in orthopaedic reconstruction products.

Bull

- Strength in attractive market niches, such as arthroscopy, endoscopy and wound care
- Recent acquisitions have been positive, alongside divestment of its gynaecology business, from which shareholders are benefitting via a share buyback
- The biggest European medical device maker, which may be an M&A target.

Bear

- Growth continues to be tempered by FX and economic conditions in the emerging markets
- Consolidation of hospital buying patterns plays in favour of even bigger medical device companies
- Product pricing is likely to stay challenging, as healthcare funding remains under pressure

Analysts

| | |
|------------------|---------------------|
| Dr Linda Pomeroy | +44 (0)20 3077 5738 |
| Lala Gregorek | +44 (0)20 3681 2527 |

healthcare@edisongroup.com

**Smith & Nephew is a client of
Edison Investment Research
Limited**

Edison, the investment intelligence firm, is the future of investor interaction with corporates. Our team of over 100 analysts and investment professionals work with leading companies, fund managers and investment banks worldwide to support their capital markets activity. We provide services to more than 400 retained corporate and investor clients from our offices in London, New York, Frankfurt and Sydney. Edison is authorised and regulated by the [Financial Conduct Authority](#). Edison Investment Research (NZ) Limited (Edison NZ) is the New Zealand subsidiary of Edison. Edison NZ is registered on the New Zealand Financial Service Providers Register (FSP number 247505) and is registered to provide wholesale and/or generic financial adviser services only. Edison Investment Research Inc (Edison US) is the US subsidiary of Edison and is regulated by the Securities and Exchange Commission. Edison Investment Research Limited (Edison Aus) [46085869] is the Australian subsidiary of Edison and is not regulated by the Australian Securities and Investment Commission. Edison Germany is a branch entity of Edison Investment Research Limited [4794244]. www.edisongroup.com

DISCLAIMER

Copyright 2017 Edison Investment Research Limited. All rights reserved. This report has been commissioned by Smith & Nephew and prepared and issued by Edison for publication globally. All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report. Opinions contained in this report represent those of the research department of Edison at the time of publication. The securities described in the Investment Research may not be eligible for sale in all jurisdictions or to certain categories of investors. This research is issued in Australia by Edison Aus and any access to it, is intended only for "wholesale clients" within the meaning of the Australian Corporations Act. The Investment Research is distributed in the United States by Edison US to major US institutional investors only. Edison US is registered as an investment adviser with the Securities and Exchange Commission. Edison US relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. As such, Edison does not offer or provide personalised advice. We publish information about companies in which we believe our readers may be interested and this information reflects our sincere opinions. The information that we provide or that is derived from our website is not intended to be, and should not be construed in any manner whatsoever as, personalised advice. Also, our website and the information provided by us should not be construed by any subscriber or prospective subscriber as Edison's solicitation to effect, or attempt to effect, any transaction in a security. The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are "wholesale clients" for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. This document is provided for information purposes only and should not be construed as an offer or solicitation for investment in any securities mentioned or in the topic of this document. A marketing communication under FCA rules, this document has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research. Edison has a restrictive policy relating to personal dealing. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report. Edison or its affiliates may perform services or solicit business from any of the companies mentioned in this report. The value of securities mentioned in this report can fall as well as rise and are subject to large and sudden swings. In addition it may be difficult or not possible to buy, sell or obtain accurate information about the value of securities mentioned in this report. Past performance is not necessarily a guide to future performance. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a "personalised service" and, to the extent that it contains any financial advice, is intended only as a "class service" provided by Edison within the meaning of the FAA (ie without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision. To the maximum extent permitted by law, Edison, its affiliates and contractors, and their respective directors, officers and employees will not be liable for any loss or damage arising as a result of reliance being placed on any of the information contained in this report and do not guarantee the returns on investments in the products discussed in this publication. FTSE International Limited ("FTSE") (c) FTSE [2017]. "FTSE(r)" is a trade mark of the London Stock Exchange Group companies and is used by FTSE International Limited under license. All rights in the FTSE indices and/or FTSE ratings vest in FTSE and/or its licensors. Neither FTSE nor its licensors accept any liability for any errors or omissions in the FTSE indices and/or FTSE ratings or underlying data. No further distribution of FTSE Data is permitted without FTSE's express written consent.